Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $138.72 USD
Change Today +0.69 / 0.50%
Volume 351.7K
IDXX On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

idexx laboratories inc (IDXX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/15 - $168.51
52 Week Low
09/23/14 - $113.49
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

idexx laboratories inc (IDXX) Related Bloomberg News

View More Bloomberg News

idexx laboratories inc (IDXX) Related Businessweek News

No Related Businessweek News Found

idexx laboratories inc (IDXX) Details

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice management systems and services, and digital imaging systems for veterinarians; and biological materials testing and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic, health-monitoring, and food safety testing products for livestock, poultry, and dairy; products that test water for certain microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company sells its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

6,400 Employees
Last Reported Date: 02/17/15
Founded in 1983

idexx laboratories inc (IDXX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $800.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $496.2K
Executive Vice President
Total Annual Compensation: $416.9K
Executive Vice President
Total Annual Compensation: $416.9K
Executive Vice President
Total Annual Compensation: $416.9K
Compensation as of Fiscal Year 2014.

idexx laboratories inc (IDXX) Key Developments

IDEXX Laboratories, Inc. Launches Hookworm and Roundworm Antigen Tests, Two New Intestinal Parasite Screening Tests for Pets

IDEXX Laboratories, Inc. has launched the hookworm and roundworm antigen tests, two new intestinal parasite screening tests for pets. The new hookworm and roundworm antigen tests offer a higher standard of care in intestinal parasite screening because they can catch the presence of an adult worm early in the infection cycle that current egg detection methods may miss, enabling faster diagnosis and treatment for pets. The new intestinal parasite screening tests from IDEXX are an exciting breakthrough as the new antigen tests can detect the existence of adult worms earlier in the infection cycle and when there is intermittent shedding of the parasite ova. This provides more accurate and consistent diagnosis, which enables veterinarians to provide the best medical care. The introduction of these new antigen tests from IDEXX Reference Laboratories offers an easier, more accurate solution. In particular, these fecal antigen tests can detect the presence of intestinal parasite infections up to thirty days earlier than current methods, and they can detect these infections in more pets.

IDEXX Laboratories, Inc. Announces Directorate Changes

Mr. Robert J. Murray retired as a member of the board of directors of IDEXX Laboratories, Inc., effective at the annual meeting of stockholders of the company held on May 6, 2015, which is one year prior to the expiration of his term as a Class III Director. Mr. Murray's retirement was pursuant to and in accordance with the Company's Corporate Governance Guidelines, which require that Directors retire at the next annual meeting of stockholders after the date on which Directors reach the age of 73. At a meeting of the Board immediately following the 2015 Annual Meeting, the Board reassigned Dr. Barry C. Johnson, who was re-elected as a Class I Director at the 2015 Annual Meeting, from Class I to Class III, in order to fill the vacancy in Class III resulting from Mr. Murray's retirement. As a Class III Director, Dr. Johnson's term will expire at the Company's 2016 annual meeting of stockholders. As a result of the vacancy in Class I created by the reassignment of Dr. Johnson from Class I to Class III, the Board reduced the number of Directors constituting the Board from nine to eight and the number of Class I Directors from three to two.

IDEXX Laboratories, Inc. Launches Canine Influenza Test Targeting H3N2 in Response to Outbreak

IDEXX Laboratories, Inc. announced that the company has developed, validated and made available a new test for the detection of H3N2 canine influenza virus. An avian-origin H3N2 strain identified in Asia around 2006 was determined to be the cause of a recent widespread canine influenza outbreak in the Chicago area. This highly contagious strain had previously been reported only in Asia but is now spreading among the dog population in the U.S. The IDEXX RealPCR Laboratory recently confirmed cases in the following states: Alabama, California, Texas, New York, Iowa, Michigan, Wisconsin and Indiana, in addition to the outbreak in the Chicago area. As soon as the H3N2 strain was reported in the U.S., IDEXX invested in research and development and in less than four weeks produced and validated a test to detect the H3N2 strain. The new H3N2 Influenza Virus RealPCR Test allows rapid, reliable and specific testing for the strain responsible for the outbreak. IDEXX has added the H3N2 Influenza Virus RealPCR Test to existing IDEXX Comprehensive Canine Respiratory Disease (CRD) RealPCR panels at no additional cost to customers. The H3N2 test is also available as a stand-alone test. H3N2 influenza causes cough, fever, lack of appetite, weight loss and interstitial pneumonia and can be fatal. The signs of this illness in dogs are cough, runny nose and fever; however, some dogs are asymptomatic. Canine influenza also can impact cats.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDXX:US $138.72 USD +0.69

IDXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
MEDNAX Inc $71.37 USD +0.28
PerkinElmer Inc $53.39 USD 0.00
Siemens Ltd 1,352 INR -22.35
Sirona Dental Systems Inc $98.49 USD +0.20
Teleflex Inc $129.72 USD +0.81
View Industry Companies

Industry Analysis


Industry Average

Valuation IDXX Industry Range
Price/Earnings 37.8x
Price/Sales 4.3x
Price/Book 190.8x
Price/Cash Flow 35.7x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDEXX LABORATORIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at